First FDA ODAC meeting without Pazdur highlights conceptual challenges with trial
BioSpace
The advisory committee meeting--the FDA's first drug-related adcomm in nine months--could have been a "more conceptual discussion" about the design of AstraZeneca's Phase 3 trial of camizestrant in HER2
pharminent
May 4, 2026 (Last updated: May 4, 2026)
BioSpace
The advisory committee meeting–the FDA’s first drug-related adcomm in nine months–could have been a “more conceptual discussion” about the design of AstraZeneca’s Phase 3 trial of camizestrant in HER2